Skip to main navigationSkip to main content
The University of Southampton
We're launching a new website soon and would love your feedback. See the new design
SAFA study

Researchers and Clinicians

The SAFA trial is funded by the NIHR HTA programme to determine the clinical and cost-effectiveness spironolactone compared with placebo in addition to standard care in the treatment of moderate or severe persistent facial acne in adult women.

SAFA is a pragmatic multicentre double-blind randomised placebo-controlled trial recruiting from dermatology centres in Birmingham, Bristol, Cardiff, Epsom, Harrogate, London, Nottingham, Poole, Portsmouth and Swansea. General practices local to the sites will act as Participant Identification Centres.

We recruited 410 women aged 18 years and over.

Recruitment began in June 2019 and we expect to produce our final report in September 2022. Please see the protocol for more details about how we are carrying out the trial. Please see the Spironolactone Information Sheet if you would like to know more about the trial drug.

For general queries about the study, please contact the SAFA study manager.

Susanne Renz, PhD (SAFA Study Manager)


Telephone: 02381205538

Fax: 08447740621

Postal address:

Southampton Clinical Trials Unit

University of Southampton

Mailpoint 131

Southampton General Hospital

Tremona Road


SO16 6YD

Useful Downloads

Need the software?PDF Reader
Privacy Settings